欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2002, Vol. 7 ›› Issue (2): 153-155.

• 临床研究 • 上一篇    下一篇

口服华法令抗凝治疗中凝血功能的变化

张红超, 蓝鸿钧1, 孙宗全1, 于鲁峰, 秦斌, 万士杰, 王维新   

  1. 空军总医院心脏外科, 北京 100036;
    1同济医科大学协和医院心脏内科, 武汉 430022
  • 收稿日期:2001-11-29 修回日期:2001-12-25 出版日期:2002-04-26 发布日期:2020-11-27
  • 通讯作者: 张红超, 男, 博士, 主治医师。Tel:010-66928163  E-mail:zhanghc2002 @sohu.com

Variation of coagulation system in the different periods of oral warfarm anticoagulation

ZHANG Hong-Chao, LAN Hong-Jun1, SUN Zong-Quan1, YU Lu-Fong, QIN Bin, WAN Shi-Jie, WANG Wei-Xin   

  1. Department of Cardiovascular Surgery, Airforce General Hospital Beijing 100036;
    1Department of Cardiovascular Surgery,Union Hospital, Tongji Medical University, Wuhan 430022
  • Received:2001-11-29 Revised:2001-12-25 Online:2002-04-26 Published:2020-11-27

摘要: 目的: 观察口服华法令抗凝(OWAT) 不同阶段凝血状态的改变, 尤其注意uFPA 在判断OWAT效果中的价值。方法: 换瓣术后14 d(换瓣14 d 组)和术后0.5 ~ 2 年(术后随访组) 病人各20 例, 要求INR(国际正常比值) 值在1.8 ~ 2.8, 正常组为10 例健康志愿者。取静脉血7 ml, 留尿液5 ml, 测定蛋白C(PC)、6-酮-前列腺1α(6-K-F1α)、血小斑颗粒膜蛋白-140(GMP-140) 和D-二聚体(D-2-Dimer) 及抗凝血酶Ⅲ(AT Ⅲ)、组织型纤溶酶激活物(t-PA) 和尿液纤维蛋白肽A(FPA)。 结果: 换瓣14 d 组uFPA 显著低于正常正常组, D2D 却显著高于正常组。术后随访组病人的uFPA 比术后14 d 更低, 且与PT 相关性好、其值稳定于较小的变化范围(1.0 ~ 3.2 μg·g-1Cr);D2D 比换瓣14 d 组有所降低, 但二者无显著差异。AT Ⅲ在换瓣14 d 组低于正常组, 但在术后随访组却显著高于正常组;PC 在换瓣14 d 组低于正常组, 在术后随访组却进一步降低;t-PA 和6-K-F1α在OWAT 期间高于正常组, 换瓣14 d 组和随访之间无差异。结论: OWAT 早期凝血系统的变化十分复杂,分析其并发症原因应考虑机体凝血系统包括纤溶等的整体状态;以μFPA 判断OWAT 中病人凝血过程的激活水平比PT 更为准确、敏感, 在纤溶系统相对稳定的情况下, 能判断OWAT 的整体抗凝效果。

关键词: 华法令, 抗凝, 心脏瓣膜, 尿纤维蛋白肽A

Abstract: AIM: To observe the coagulation state in different periods of oral warfarin anticoagulation (OWAT), and to estimate the role of uFPA in evaluating OWAT effect.METHODS: Initial group (n=20) and follow-up group (n=20) were the patients respectively at 14 days and 0.5 to 20 years after heart valve replacement with a range of INR 1.8-2.8.Ten healthy volunteers were regarded as control group.The blood and urine samples were taken and measured.The contents of protein C (PC ), platelet granulate membrane protein 140 (GMP140 ), 6-keto-PGF1α(6-K-F1α) and D-2-Dimer (D2D), the activity of antithrombin Ⅲ (AT Ⅲ), and tissue-plasminogen activator (t-PA) urine fibrinopeptide A (uFPA) were measured.RESULTS: Coagulation process was inhibited during OWAT as well as fibrinolysis process activited at some extent.At the same levels of INR, coagulation process during OWAT was inhibited at a more low and steady level in the follow-up group than in the initial group.CONCLUSION: The variation of coagulation system is complex and fibrinolysis should be considered in analyising the OWAT complications, and uFPA is more accurate and senstive than INR to judge the activited levels of coagulation process during OWAT.If the fibrinolysis is relatively steady, it can reflect the whole anticoagulation effects of OWAT.

Key words: fibrinopeptide A, warfarin, heart valve, Anticoagulation

中图分类号: